




RealRate

PHARMACEUTICAL 2023

Emergent BioSolutions Inc.
Rank 223 of 446

EMERGENT





PHARMACEUTICAL 2023

Emergent BioSolutions Inc.
Rank 223 of 446

EMERGENT

The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 44% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	1,210,700
Cost of Goods Sold	693,700
Intangible Assets	947,000
Liabilities, Current	1,229,900
Liabilities, Non-Current	481,900
Other Assets	191,300
Other Compr. Net Income	19,200
Other Expenses	68,700
Other Liabilities	71,800
Other Net Income	-49,000
Other Revenues	1,120,900
Property and Equipment	817,600
Research and Development	193,000
Selling, General and Administrative Expense	340,300

Output Variable	Value in 1000 USD
Assets	3,166,600
Liabilities	1,783,600
Expenses	1,295,700
Revenues	1,120,900
Stockholders Equity	1,383,000
Net Income	-223,800
Comprehensive Net Income	-214,200
Economic Capital Ratio	87%